Stock Research for ACST

ACST

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ACST Stock Chart & Research Data

The ACST chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACST chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ACST Due diligence Resources & Stock Charts

The ACST stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACST Detailed Price Forecast - CNN Money CNN View ACST Detailed Summary - Google Finance
Yahoo View ACST Detailed Summary - Yahoo! Finance Zacks View ACST Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ACST Trends & Analysis - Trade-Ideas Barrons View ACST Major Holders - Barrons
NASDAQ View ACST Call Transcripts - NASDAQ Seeking View ACST Breaking News & Analysis - Seeking Alpha
Spotlight View ACST Annual Report - CompanySpotlight.com OTC Report View ACST OTC Short Report - OTCShortReport.com
TradeKing View ACST Fundamentals - TradeKing Charts View ACST SEC Filings - Bar Chart
WSJ View Historical Prices for ACST - The WSJ Morningstar View Performance/Total Return for ACST - Morningstar
MarketWatch View the Analyst Estimates for ACST - MarketWatch CNBC View the Earnings History for ACST - CNBC
StockMarketWatch View the ACST Earnings - StockMarketWatch MacroAxis View ACST Buy or Sell Recommendations - MacroAxis
Bullish View the ACST Bullish Patterns - American Bulls Short Pains View ACST Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ACST Stock Mentions - StockTwits PennyStocks View ACST Stock Mentions - PennyStockTweets
Twitter View ACST Stock Mentions - Twitter Invest Hub View ACST Investment Forum News - Investor Hub
Yahoo View ACST Stock Mentions - Yahoo! Message Board Seeking Alpha View ACST Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ACST - SECform4.com Insider Cow View Insider Transactions for ACST - Insider Cow
CNBC View ACST Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACST - OTC Markets
Yahoo View Insider Transactions for ACST - Yahoo! Finance NASDAQ View Institutional Holdings for ACST - NASDAQ


Stock Charts

FinViz View ACST Stock Insight & Charts - FinViz.com StockCharts View ACST Investment Charts - StockCharts.com
BarChart View ACST Stock Overview & Charts - BarChart Trading View View ACST User Generated Charts - Trading View




Latest Financial News for ACST


Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2019
Posted on Tuesday August 14, 2018

LAVAL, QUÉBEC, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the first quarter ending June 30, 2018. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “Our two TRILOGY Phase 3 studies remain on track to complete enrollment this year. “We have nearly completed the manufacturing of all of the clinical trial materials needed for TRILOGY, and have further diversified our supply of raw krill oil by having completed the validation of a new supplier.


Acasti: 2Q Earnings Snapshot
Posted on Tuesday August 14, 2018

The Laval, Quebec-based company said it had a loss of 18 cents per share. The company's shares closed at 47 cents. A year ago, they were trading at $1.33. _____ This story was generated by Automated Insights ...


Acasti Pharma Announces Mailing of Management Information Circular and Amendment to Stock Option Plan
Posted on Tuesday July 31, 2018

LAVAL, QUÉBEC, July 31, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced the mailing of its management information circular for the upcoming annual meeting of the shareholders (the “Meeting”) of the Company to be held at 1000 De La Gauchetière Street West, Suite 2100, Montreal, Québec H3B 4W5, Canada, on August 28, 2018 at 10:00 a.m. The Company also announces that, subject to the approval of shareholders at the Meeting, the Board of Directors has amended the Company’s stock option plan (the “Stock Option Plan”) in order to decrease the fixed number of common shares of the Company (“Common Shares”) that may be issued upon the exercise of all options granted under the Stock Option Plan from the previous proposal of 7,325,612 shares, as announced on July 2, 2018, which would have represented 20% of the issued and outstanding Common Shares as of June 27, 2018, to 5,494,209 shares, representing 15% of the issued and outstanding Common Shares as of June 27, 2018.


Benzinga Pro's 5 Stocks To Watch Today
Posted on Tuesday July 24, 2018

Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Protalix Biotherapeutics Inc (NYSE: PLX ) stock gained ...


Stock Market & Investing Books

Enter a stock symbol to view the stock details.